Piritinol

Piritinol is a water-soluble, semisynthetic analogue of pyridoxine (vitamin B6), formed by joining two pyridoxine units through a disulfide bridge; it is generally classified as a nootropic and is often described as having antioxidant properties ^[1]. Because of this modification it is handled by the body differently from ordinary vitamin B6, and it is not simply a B6 supplement.

The compound was introduced by Merck in the early 1960s and became established in Europe under brand names such as Encephabol and Encefabol. From the 1970s onward it was available there as both a prescription and over-the-counter medicine, and from the early 1990s it circulated in the United States as a dietary supplement rather than an approved drug ^[1].

Approved and traditional uses vary by country and have included symptomatic treatment of chronic brain dysfunction and dementia, supportive care following craniocerebral trauma, learning difficulties in children, and, in some markets such as France, rheumatoid arthritis as a slow-acting disease-modifying agent ^[4]. The clinical record is mixed. A crossover study in healthy male volunteers reported improvements in arousal measures including critical flicker fusion and choice reaction time ^[1], and a placebo-controlled trial in older patients with organic mental disorders found gains on clinical and performance ratings ^[2]. In contrast, a double-blind study of children in slow-learner classes showed no significant average benefit on cognitive testing ^[3], illustrating the inconsistency of the evidence.

In regulatory terms piritinol is a prescription medicine in parts of Europe, typically supplied as coated tablets or an oral suspension, while it has no drug approval in the United States ^[1][2]. Although it is usually well tolerated, rare but serious adverse reactions have been documented, most notably severe cholestatic hepatitis ^[5], along with occasional reports of acute pancreatitis and skin eruptions; these have contributed to caution about long-term use.

Usually tolerated, but there are notable rare reports of hepatotoxicity, cholestasis, skin reactions, and pemphigus-like effects, likely tied to the thiol group. GI upset and taste changes can occur. Because of the liver and immune-related concerns, monitoring and caution are sensible, and it is not something to take lightly long term.

Piritinol, also called pyritinol or pyrithioxine and sold under names such as Encephabol, was first synthesized in 1961 by Merck by joining two molecules of pyridoxine (vitamin B6) through a disulfide bridge. From the 1970s onward it was marketed across several European and Asian countries as a prescription and over-the-counter treatment for cognitive and learning disorders, and it was later also trialed as a disease-modifying agent in rheumatoid arthritis.

Piritinol is regarded as an older semisynthetic B6 derivative with a mixed reputation. It retains a following as an inexpensive cholinergic nootropic said to aid mental energy and hangover recovery, supported by some older clinical work in dementia. Medical sources temper this with documented safety concerns, including cases of hepatotoxicity, cholestatic hepatitis, acute pancreatitis, and hypersensitivity reactions, which have curtailed its use in several markets and lead cautious observers to treat it as less benign than its vitamin origin might suggest.